EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Presence of myositis-specific autoantibodies may predict favourable outcomes to rituximab in patients with idiopathic inflammatory myositis: Retrospective observational study

Emin Oğuz iD, Nevzat Koca iD, Murat Bektaş iD

Modern Rheumatology · 2025

DOI: 10.1093/mr/roaf097 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Modern Rheumatology, 2025. Verfasst von Emin Oğuz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Istinye University Bahçeşehir Liv Hospital, Istanbul, Turkey. Hauptthemen laut MEDLINE: Rituximab, Myositis, Autoantibodies, Immunologic Factors. Die Arbeit nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to evaluate the autoantibody profile, including myositis-associated autoantibodies (MAAs) and myositis-specific autoantibodies (MSAs), and their influence on outcomes of rituximab (RTX) treatment in patients with IIM.

Methods

This retrospective observational study included data from patients with idiopathic inflammatory myositis (IIM) who met at least one of the following criteria: Bohan and Peter, ACR/EULAR 2017, and European Neuromuscular Center (ENMC) criteria.

Results

Fifty-three patients, 72% of whom were female, were included. Among them, 32.1% had a clinical diagnosis of dermatomyositis, 35.8% antisynthetase syndrome (ASS), 15.3% overlap syndrome, 11.3% polymyositis, and 5.7% had immune-mediated necrotizing myopathy. RTX was used in 49% of the patients, and nearly half of them (46%) had ASS. Remission was achieved in 77%, a partial response was observed in 11.5%, and unresponsiveness/active disease was observed in 11.5% of patients receiving RTX. Relapse was lower, and mortality tended to be lower in patients receiving RTX. In multivariate analysis, MSA positivity was associated with remission in those receiving RTX.

Conclusions

In our study, RTX was safe and effective in patients with IIM who had an inadequate response or severe disease at admission. Furthermore, the presence of MSAs may predict a favourable response to RTX treatment in patients with IIM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabMyositisAutoantibodiesImmunologic FactorsAntirheumatic AgentsHumansFemaleRetrospective StudiesMiddle AgedMaleTreatment OutcomeAdultAged

Stichwörter der Autor:innen

Anti-synthetase syndromeidiopathic inflammatory myositismyositis-associated antibodiesmyositis-specific antibodiesrituximab

Substanzen

RituximabAutoantibodiesImmunologic FactorsAntirheumatic Agents

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Internal Medicine, Istinye University Bahçeşehir Liv Hospital, Istanbul, Turkey.
  • Division of Rheumatology, Department of Internal Medicine, Van District Training and Research Hospital, Van, Turkey.
  • Division of Rheumatology, Department of Internal Medicine, Istinye University Vadi Liv Hospital, Istanbul, Turkey.
  • Division of Rheumatology, Department of Internal Medicine, Istanbul Aydın University, Istanbul, Turkey.

ORCID-Profile: Emin Oğuz, Nevzat Koca, Murat Bektaş

Zitieren

APA

Oğuz, E., Koca, N., & Bektaş, M. (2025). Presence of myositis-specific autoantibodies may predict favourable outcomes to rituximab in patients with idiopathic inflammatory myositis: Retrospective observational study. Modern Rheumatology. https://doi.org/10.1093/mr/roaf097

Vancouver

Oğuz E, Koca N, Bektaş M. Presence of myositis-specific autoantibodies may predict favourable outcomes to rituximab in patients with idiopathic inflammatory myositis: Retrospective observational study. Modern Rheumatology. 2025. doi:10.1093/mr/roaf097

BibTeX
@article{Ouz2025,
  author = {Oğuz, Emin and Koca, Nevzat and Bektaş, Murat},
  title = {Presence of myositis-specific autoantibodies may predict favourable outcomes to rituximab in patients with idiopathic inflammatory myositis: Retrospective observational study},
  journal = {Modern Rheumatology},
  year = {2025},
  doi = {10.1093/mr/roaf097}
}
Kostenlos starten →